~~<i id='631CA71EC4'><strike id='631CA71EC4'><tt id='631CA71EC4'><pre id='631CA71EC4'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：Wikipedia 2025-09-30 15:16:05 - browse：5519

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Young boy dies in trial for Pfizer Duchenne gene therapy

focus

entertainment

focus

entertainment

leisure time

AdobeEachyear,abouthalfofallU.S.doctorsacceptmoneyorgiftsfromdruganddevicecompanies,totalingmorethan

WSS

More hospitals are billing patients as online messages surge

Bird flu in dairy cattle: New measures to control spread to humans

Overprescribed: High cost isn't America's only drug problem

Four alarming medical procedures we’re glad history forgot

Robert Kennedy Jr.'s presidential campaign attracts GOP

UnitedHealth, in a surprise, takes aim at Steward’s physician group

focus

fashion

focus

Medicare details structure of new drug price negotiation program

Scientists uncover potential path to treating deadly childhood tumor

Apple is now the first public company to be valued at $3 trillion

Drug companies' payments and gifts affect physicians' prescribing

Medical records are filled with copy

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

How one medical school became remarkably diverse

Four alarming medical procedures we’re glad history forgot

entertainment

Insurer loopholes limit power of law against surprise medical bills

Johnson & Johnson sues to stop Medicare negotiation

Scientists uncover potential path to treating deadly childhood tumor

Scientists uncover potential path to treating deadly childhood tumor

House passes resolution saying Israel isn't a 'racist or apartheid state'

Gut bacteria may contribute to kidney autoimmunity, study finds

focus

entertainment

leisure time

leisure time